SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-20-058103
Filing Date
2020-05-07
Accepted
2020-05-07 16:12:43
Documents
44
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tm2014574d1_10q.htm 10-Q 614373
2 EXHIBIT 31.1 tm2014574d1_ex31-1.htm EX-31.1 11306
3 EXHIBIT 31.2 tm2014574d1_ex31-2.htm EX-31.2 11358
4 EXHIBIT 32.1 tm2014574d1_ex32-1.htm EX-32.1 4779
5 EXHIBIT 32.2 tm2014574d1_ex32-2.htm EX-32.2 4278
  Complete submission text file 0001104659-20-058103.txt   2864719

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ckpt-20200331.xml EX-101.INS 535160
7 XBRL TAXONOMY EXTENSION SCHEMA ckpt-20200331.xsd EX-101.SCH 30346
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ckpt-20200331_cal.xml EX-101.CAL 21268
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ckpt-20200331_def.xml EX-101.DEF 118288
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ckpt-20200331_lab.xml EX-101.LAB 206231
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ckpt-20200331_pre.xml EX-101.PRE 194180
Mailing Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET 9TH FLOOR NEW YORK NY 10014 212-554-4366
Checkpoint Therapeutics, Inc. (Filer) CIK: 0001651407 (see all company filings)

IRS No.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38128 | Film No.: 20856502
SIC: 2834 Pharmaceutical Preparations